신경병증성 통증 시장 : 규모, 점유율, 성장, 업계 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of neuropathic pain Market

The global neuropathic pain market is witnessing steady growth due to the rising prevalence of chronic diseases and increasing demand for effective pain management therapies. The market was valued at USD 8.26 billion in 2025, increased to USD 8.83 billion in 2026, and is projected to reach USD 16.78 billion by 2034. North America dominated the market with a 50.66% share in 2025, supported by strong pharmaceutical presence and high awareness levels.

Neuropathic pain arises from damage or dysfunction in the nervous system and is often chronic, significantly affecting patients' quality of life. Common treatment options include medications such as anticonvulsants and antidepressants, along with medical devices and surgical interventions. Increasing cases of diabetes, cancer, and shingles are major contributors to the growing patient pool requiring treatment.

Market Trends

A key trend in the neuropathic pain market is the increasing focus on research and development for novel therapeutics. Pharmaceutical companies are actively conducting clinical trials to introduce advanced drugs with improved efficacy and fewer side effects. For instance, ongoing trials for innovative drug candidates targeting polyneuropathy and trigeminal neuralgia are expected to expand treatment options.

Another notable trend is the shift toward targeted and personalized therapies. Companies are leveraging advanced technologies and precision medicine approaches to develop treatments tailored to specific patient conditions. This trend is expected to improve treatment outcomes and drive market growth over the forecast period.

Market Drivers

The growing burden of chronic diseases such as diabetes, cancer, and neurological disorders is a major driver of market growth. Globally, a significant proportion of the population suffers from diabetes, which is a leading cause of neuropathic pain. Additionally, chemotherapy-induced neuropathy is increasing due to the rising number of cancer cases worldwide.

The aging population is another important factor contributing to market expansion. Elderly individuals are more susceptible to conditions such as post-herpetic neuralgia and diabetic neuropathy, thereby increasing the demand for effective pain management solutions.

Furthermore, increasing awareness about neuropathic pain and the availability of advanced therapeutics are encouraging more patients to seek treatment. Government initiatives and improved healthcare infrastructure are also supporting market growth.

Market Restraints

Despite the positive outlook, the market faces certain challenges. Side effects associated with neuropathic pain medications, such as dizziness, nausea, and fatigue, often limit patient adherence to treatment. These adverse effects encourage patients to explore alternative treatment options, including medical devices and surgical procedures.

Additionally, high treatment costs and limited accessibility in developing regions may hinder market growth. The lack of awareness and inadequate healthcare infrastructure in some regions also restricts the adoption of advanced therapies.

Segmentation Analysis

By drug class, the anticonvulsants segment dominated the market with a 28.92% share in 2026, driven by the widespread use of drugs such as gabapentin and pregabalin for diabetic neuropathy. Other segments, including antidepressants and opioids, also contribute significantly, while emerging therapies are expected to witness faster growth.

By application, chemotherapy-induced neuropathy held the largest share of 39.48% in 2026, due to the increasing number of cancer patients undergoing treatment. The diabetic neuropathy segment is expected to grow rapidly owing to the rising prevalence of diabetes globally.

By route of administration, the oral segment dominated with a 77.15% share in 2026, supported by the availability of a wide range of oral medications. Parenteral administration is also gaining traction due to ongoing research in injectable therapies.

By distribution channel, retail pharmacies led the market with a 68.61% share in 2026, attributed to easy accessibility of medications. Online pharmacies are emerging as a fast-growing segment due to increasing consumer preference for convenient purchasing options.

Regional Insights

North America accounted for USD 4.18 billion in 2025 and is projected to reach USD 4.51 billion in 2026, driven by strong R&D activities and high disease prevalence. The U.S. remains the largest contributor in the region.

Europe held USD 2.28 billion in 2025 and is expected to reach USD 2.42 billion in 2026, supported by increasing cases of diabetes and cancer. Asia Pacific, valued at USD 1.0 billion in 2025, is projected to grow to USD 1.07 billion in 2026, driven by rising investments in pharmaceutical research.

Latin America and the Middle East & Africa are emerging markets, with increasing awareness and improving healthcare infrastructure supporting growth.

Competitive Landscape

The market is highly competitive, with key players such as Pfizer Inc., Novartis AG, Viatris Inc., and Abbott focusing on product innovation and strategic collaborations. Companies are investing in acquisitions and partnerships to strengthen their product portfolios and expand their global presence.

Recent developments, including new drug approvals and clinical trials, highlight the industry's commitment to advancing neuropathic pain treatment options.

Conclusion

The neuropathic pain market is expected to grow from USD 8.26 billion in 2025 to USD 16.78 billion by 2034, driven by the rising prevalence of chronic diseases, increasing geriatric population, and ongoing advancements in therapeutics. While challenges such as side effects and high costs persist, continuous innovation and expanding treatment options are expected to support sustained market growth.

Segmentation By Drug Class

• Anticonvulsants
• Tricyclic Antidepressants (TCA)
• Opioids
• Capsaicinoids
• Others

By Application

• Diabetic Neuropathy
• Chemotherapy Induced Neuropathy
• Sciatic Neuropathy
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and BY Country/Sub-region)
  • Japan
  • China
  • Australia
  • India
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • South Africa
  • GCC
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Neuropathic pain - by Key Countries/Sub-regions, 2025
• 4.2. Pipeline Analysis - by Key Players
• 4.3. New Product launches - by Key Players
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Anticonvulsants
  • 5.1.2. Tricyclic Antidepressant (TCA)
  • 5.1.3. Opioids
  • 5.1.4. Capsaicinoids
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Diabetic Neuropathy
  • 5.2.2. Chemotherapy Induced Neuropathy
  • 5.2.3. Sciatic Neuropathy
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Pharmacy
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Anticonvulsants
  • 6.1.2. Tricyclic Antidepressant (TCA)
  • 6.1.3. Opioids
  • 6.1.4. Capsaicinoids
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Diabetic Neuropathy
  • 6.2.2. Chemotherapy Induced Neuropathy
  • 6.2.3. Sciatic Neuropathy
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Pharmacy
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Anticonvulsants
  • 7.1.2. Tricyclic Antidepressant (TCA)
  • 7.1.3. Opioids
  • 7.1.4. Capsaicinoids
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Diabetic Neuropathy
  • 7.2.2. Chemotherapy Induced Neuropathy
  • 7.2.3. Sciatic Neuropathy
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Pharmacy
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Anticonvulsants
  • 8.1.2. Tricyclic Antidepressant (TCA)
  • 8.1.3. Opioids
  • 8.1.4. Capsaicinoids
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Diabetic Neuropathy
  • 8.2.2. Chemotherapy Induced Neuropathy
  • 8.2.3. Sciatic Neuropathy
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. Australia
  • 8.5.3. China
  • 8.5.4. India
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Anticonvulsants
  • 9.1.2. Tricyclic Antidepressant (TCA)
  • 9.1.3. Opioids
  • 9.1.4. Capsaicinoids
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Diabetic Neuropathy
  • 9.2.2. Chemotherapy Induced Neuropathy
  • 9.2.3. Sciatic Neuropathy
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Pharmacy
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Anticonvulsants
  • 10.1.2. Tricyclic Antidepressant (TCA)
  • 10.1.3. Opioids
  • 10.1.4. Capsaicinoids
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Diabetic Neuropathy
  • 10.2.2. Chemotherapy Induced Neuropathy
  • 10.2.3. Sciatic Neuropathy
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Pharmacy
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. South Africa
  • 10.5.2. GCC
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Almatica
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Azurity Pharmaceuticals, Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Pfizer Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Viatris Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Supernus Pharmaceuticals, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Novartis AG
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Accord Healthcare
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Focus Health Group
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Amneal Pharmaceuticals LLC
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Abbott
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Teva Pharmaceutical Industries Ltd.
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)